Pancreatic ductal adenocarcinoma marker and screening method thereof

Abstract

The invention discloses a pancreatic ductal adenocarcinoma marker and a screening method thereof, which belongs to the field of clinical test and diagnosis. In view of the problem that the detection sensitivity and the detection specificity of the existing pancreatic ductal adenocarcinoma diagnosis marker are poor, serum of an early patient of early stage pancreatic duct adenocarcinoma is subjected to a trace metabolomics analysis by the high-performance liquid chromatography-tandem mass spectrometry technology, and different metabolites between normal human and the early stage pancreatic ductal adenocarcinoma patients are found. The different metabolites between normal human and pancreatic ductal adenocarcinoma patients are further analyzed by this technique to find the specific differentmetabolites C10:1 acyl carnitine and lysophosphatidyl choline LysoPC (14:0) of pancreatic ductal adenocarcinoma patients caused by cancer, i.e., the diagnostic molecules of the pancreatic ductal adenocarcinoma. According to the pancreatic ductal adenocarcinoma marker and the screening method thereof, the method can assist CA19-9 in diagnosing pancreatic duct adenocarcinoma patients, and can improve the diagnosis rate for the CA19-9 negative patients by 85%. The method is suitable for the screening of tumor markers.

Description

technical field [0001] The invention belongs to the field of clinical examination and diagnosis, and in particular relates to a pancreatic ductal adenocarcinoma marker and a screening method thereof. Background technique [0002] Pancreatic ductal adenocarcinoma is a type of pancreatic cancer. It is a malignant tumor of the digestive tract with a high degree of malignancy and difficult diagnosis and treatment. Early diagnosis techniques for pancreatic ductal adenocarcinoma mainly include tumor biomarkers, imaging diagnosis, and gene diagnosis. But these several methods still have serious deficiencies: [0003] 1) At present, the serum marker of ductal adenocarcinoma of ductal epithelium is CA19-9, which has low sensitivity and specificity for detecting pancreatic cancer. Especially for the detection of early pancreatic cancer, the positive detection rate of CA19-9 is only 37.5%. [0004] 2) In the serum of patients with benign lesions such as cholangitis, pancreatitis and...

AI Technical Summary

Problems solved by technology

[0006] Aiming at the problem of poor detection sensitivity and specificity of the current diagnostic markers for pancreatic ductal adenocarcinoma, the present invention uses high performance liquid chromatography-tandem mass spectrometry to analyze the serum of patients with early pancreatic ductal adenocarcinoma in micrometabolomics, and finds that normal people and Differential metabolites between early pancreatic ductal adenocarcinoma populations; further use this technology to analyze differential metabolites between normal people and pancreatic ductal adenocarcinoma patients; find specific differential metabolites in patients with pancreatic ductal adenocarcinoma caused by cancer, namely Diagnostic molecules for pancreatic ductal adenocarcinoma

Images